MKI67 and neoplasm: Peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTATATE has demonstrated meaningful antitumor activity and is generally considered in patients with SSTR-positive tumors with progressive disease (Ki-67 ≥ 10%) or increasing tumor burdens, especially when tumor reduction is desirable.